ACET Adicet Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1720580 · Fiscal year ends 12/26
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.9%
TTM EPS YoY78.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-85.9%
ROA-67.5%
ROIC (approx.)-97.0%
Asset turnover—
Leverage & solvency
Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.09x
Interest coverage-1,038.62x
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $15.63M | $18.45M | $17.49M | $25.04M | $22.85M | $28.42M | $22.81M | $23.27M |
| SG&A expense | $4.17M | $3.85M | $4.08M | $6.85M | $5.10M | $3.97M | $7.07M | $7.47M |
| Operating income | -$19.80M | -$22.30M | -$21.57M | -$31.89M | -$27.95M | -$32.39M | -$29.89M | -$30.74M |
| Interest expense | $23,000 | $22,000 | $23,000 | $24,000 | $12,000 | $0 | $0 | $1,000 |
| Pretax income | -$18.88M | -$21.21M | -$20.24M | -$30.52M | -$26.86M | -$31.22M | -$28.21M | -$28.73M |
| Income tax | $1,000 | $143,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.88M | -$21.36M | -$20.24M | -$30.52M | -$26.86M | -$31.22M | -$28.21M | -$28.73M |
| EBITDA | -$18.80M | -$21.10M | -$20.23M | -$30.41M | -$26.35M | -$30.74M | -$28.29M | -$29.12M |
| EPS (basic) | -1.76 | -1.99 | -1.88 | — | -4.72 | -5.48 | -4.96 | — |
| EPS (diluted) | -1.76 | -1.99 | -1.88 | — | -4.72 | -5.48 | -4.96 | — |
| Weighted avg. shares (diluted) | 10.75M | 10.75M | 10.74M | — | 5.69M | 5.69M | 5.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $27.11M | $33.13M | $36.24M | $38.92M | $29.10M | $34.72M | $28.13M | $59.40M |
| Current assets | $103.44M | $120.76M | $140.07M | $160.93M | $106.49M | $127.74M | $153.56M | $180.14M |
| PP&E, net | $13.07M | $14.03M | $15.18M | $16.53M | $17.99M | $19.55M | $21.11M | $22.52M |
| Total assets | $128.95M | $148.17M | $169.38M | $192.35M | $140.48M | $162.97M | $191.27M | $220.22M |
| Current liabilities | $17.00M | $18.00M | $18.30M | $21.53M | $18.94M | $17.08M | $16.45M | $19.39M |
| Total liabilities | $26.25M | $28.03M | $29.32M | $33.15M | $31.34M | $29.60M | $29.82M | $33.61M |
| Shareholders' equity | $102.70M | $120.14M | $140.06M | $159.21M | $109.14M | $133.37M | $161.45M | $186.61M |
| Shares outstanding | 9.36M | 9.36M | 9.60M | 9.59M | 83.25M | 83.25M | 82.71M | 5.16M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.92M | -$19.82M | -$21.49M | -$20.91M | -$22.31M | -$26.63M | -$25.40M | -$24.10M |
| Capital expenditure | $56,000 | $202,000 | $37,000 | -$10,000 | $209,000 | $47,000 | $1.49M | $176,000 |
| Free cash flow | -$17.98M | -$20.02M | -$21.53M | -$20.90M | -$22.52M | -$26.68M | -$26.89M | -$24.28M |
| Investing cash flow | $11.60M | $16.65M | $18.88M | -$44.53M | $16.84M | $32.95M | -$2.86M | -$22.12M |
| Financing cash flow | $1,000 | $58,000 | -$65,000 | $75.23M | -$150,000 | $267,000 | -$104,000 | $137,000 |
| Depreciation & amortization | $1.00M | $1.20M | $1.34M | $1.47M | $1.60M | $1.66M | $1.60M | $1.62M |
| Stock-based compensation | $1.50M | $1.40M | $1.30M | $5.65M | $2.50M | $2.90M | $3.18M | $3.77M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.